Genmab A (GMAB) Research & Development (2018 - 2026)
Genmab A (GMAB) posted Research & Development of -$440.0 million for Q1 2026, up 59.26% on a QoQ basis from -$1.1 billion in Q3 2025, and down 22.56% year-over-year from -$568.2 million in Q1 2025.
Genmab A (GMAB) Research & Development (2018 - 2026) Analysis & Trends
Genmab A's Research & Development history runs 6 years deep, the most recent figure standing at -$440.0 million for Q1 2026.
- Quarterly Research & Development fell 22.56% year-over-year to -$440.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.6 billion (down 7.43% YoY) and the FY2025 annual result came in at $1.6 billion, up 13.58% from the prior year.
- Research & Development was -$440.0 million for Q1 2026 at Genmab A, up from -$1.1 billion in the prior quarter.
- Across five years, Research & Development topped out at -$335.0 million in Q1 2024 and bottomed at -$1.1 billion in Q3 2025.
- A 3-year average of -$666.4 million and a median of -$696.0 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2025 — Research & Development retreated 3.88% — and 2026, when it dropped 22.56%.
- Genmab A's Research & Development stood at -$1.0 billion in 2024, then declined by 4.65% to -$1.1 billion in 2025, then jumped by 59.26% to -$440.0 million in 2026.
- Business Quant data shows GMAB's Research & Development at -$440.0 million in Q1 2026, -$1.1 billion in Q3 2025, and -$723.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | -440.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -440.00 Mn |
| Sep 30, 2025 | -1.08 Bn |
| Jun 30, 2025 | -723.00 Mn |
| Mar 31, 2025 | -359.00 Mn |
| Sep 30, 2024 | -1.03 Bn |
| Jun 30, 2024 | -696.00 Mn |
| Mar 31, 2024 | -335.00 Mn |
| Sep 30, 2020 | -721.00 |
| Dec 31, 2019 | -608.00 |
| Sep 30, 2019 | -607.89 Mn |
| Dec 31, 2018 | -343.24 Mn |